Impact of SGLT2 Inhibitors on Chronic Peritoneal Dialysis Patients.
Recruiting
N/A
Interventional Study
End Stage Chronic Renal Failure
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 13 and older
- Sex
- Any
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 38 (estimated)
- Sponsor
- Oman Ministry of Health · Government
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This project aims to examine the effects of six-month treatment with selective SGLT2 inhibitor dapagliflozin in patients with end-stage kidney disease on chronic peritoneal dialysis.
Methods: A prospective, open label, single-arm interventional clinical trial, will conduct at Nizwa Hospital from March 1st, 2026, to August 31th , 2026, and includes thirty (30) end-stage kidney disease diabetic and…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* o age equal to or more than13 years.
* All genders.
* All patients undergoing chronic Peritoneal Dialysis.
* Urine output equal or more than 150 ml/24 hours.
Exclusion Criteria:
* o Age less than 13 years
* Patients with type I diabetes mellitus.
* Patients with …
Contacts